argenex SE $ARGX Shares Sold by Bellevue Group AG

Bellevue Group AG trimmed its position in shares of argenex SE (NASDAQ:ARGX) by 1.4% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 571,039 shares of the company’s stock after selling 7,835 shares during the period. argenex comprises about 6.9% of Bellevue Group AG’s portfolio, making the stock its biggest position. Bellevue Group AG owned 0.93% of argenex worth $314,768,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in the company. Adage Capital Partners GP L.L.C. increased its position in shares of argenex by 114.3% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 297,113 shares of the company’s stock valued at $163,775,000 after purchasing an additional 158,476 shares during the last quarter. Franklin Resources Inc. grew its stake in shares of argenex by 103.9% during the second quarter. Franklin Resources Inc. now owns 279,803 shares of the company’s stock worth $154,233,000 after purchasing an additional 142,606 shares in the last quarter. Millennium Management LLC increased its holdings in argenex by 316.9% in the first quarter. Millennium Management LLC now owns 268,604 shares of the company’s stock valued at $158,977,000 after buying an additional 204,180 shares during the last quarter. Jennison Associates LLC increased its holdings in argenex by 6.1% in the second quarter. Jennison Associates LLC now owns 264,647 shares of the company’s stock valued at $145,879,000 after buying an additional 15,186 shares during the last quarter. Finally, Orbimed Advisors LLC raised its stake in argenex by 0.6% in the second quarter. Orbimed Advisors LLC now owns 208,000 shares of the company’s stock valued at $114,654,000 after buying an additional 1,300 shares in the last quarter. Hedge funds and other institutional investors own 60.32% of the company’s stock.

argenex Trading Down 1.3%

ARGX stock opened at $877.94 on Friday. The company has a market capitalization of $54.05 billion, a P/E ratio of 37.70, a PEG ratio of 0.89 and a beta of 0.37. The business has a 50 day simple moving average of $863.28 and a 200-day simple moving average of $716.27. argenex SE has a twelve month low of $510.05 and a twelve month high of $934.62.

argenex (NASDAQ:ARGX) last announced its earnings results on Thursday, October 30th. The company reported $4.40 EPS for the quarter, beating analysts’ consensus estimates of $4.37 by $0.03. argenex had a net margin of 41.58% and a return on equity of 29.78%. The business had revenue of $1.12 billion for the quarter, compared to analysts’ expectations of $1.07 billion. Research analysts predict that argenex SE will post 3.13 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently issued reports on ARGX. Guggenheim reaffirmed a “buy” rating and set a $1,070.00 price objective on shares of argenex in a research report on Thursday, September 18th. Evercore ISI upped their price target on argenex from $775.00 to $910.00 and gave the company an “outperform” rating in a report on Friday, October 31st. Wolfe Research reiterated a “peer perform” rating on shares of argenex in a research note on Monday, November 24th. Jefferies Financial Group set a $818.00 price objective on shares of argenex and gave the stock a “buy” rating in a research report on Tuesday, August 26th. Finally, Wedbush upped their target price on shares of argenex from $880.00 to $1,000.00 and gave the company an “outperform” rating in a report on Friday, November 14th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $968.83.

argenex Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.